ArticleJournal of medical virology2026
Loop-Mediated Isothermal Amplification Enables Reliable Kaposi Sarcoma Diagnosis Across Time and Sites in East Africa.
Article in Journal of medical virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Kaposi sarcoma (KS) is an endothelial cancer caused by the Kaposi sarcoma-associated herpesvirus (KSHV), and it remains one of the most frequently diagnosed and fatal cancers in sub-Saharan Africa. Achieving timely and accurate diagnosis for KS is a critical challenge in sub-Saharan Africa, where access to histopathology is limited and clinical diagnosis is often erroneous. Previously, a point-of-care device was developed to quantify KSHV DNA and demonstrated promising performance, achieving 97% sensitivity and 92% specificity at a 26-min threshold in a training set of patients from several Ugandan clinics. Herein, 421 skin biopsies from a different, test set of patients identified later in calendar time at the same clinical sites were examined using the same methodology. Using the previously defined cutoff threshold, the test achieved similarly high sensitivity (95%) and specificity (90%), confirming the robustness of the threshold-based assay across both clinical settings and time. This multi-site, temporally distinct validation supports the further development of a nucleic acid-based KS diagnostic test and holds strong potential for improving early KS diagnosis access in high-burden, resource-limited regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.